Is Hangzhou, a celestial creature, worth visiting?

Worth it. Tianjing Biotechnology (Hangzhou) Co., Ltd. (hereinafter referred to as "Tianjing Hangzhou") was established in June 20 19, and is a private company. The company is building its own clinical and commercial production base in Hangzhou Yaogang Town, in which the first phase of commercial production covers an area of about12,000 square meters, with the capacity of12,000 L commercial/clinical stock solution production and preparation production. In 2022, the first phase of commercial production GMP was put into production, and in 2024, the second phase of commercial production base GMP was put into production. The total investment of each phase of the project is estimated to be 5.6 billion yuan. Therefore, Tianjing Biotechnology (Hangzhou) Co., Ltd. is a regular company and is worth going. In September, 2020, the company has completed a round of financing of 654.38+0.5 billion USD. There are many innovative biopharmaceutical projects under clinical and preclinical development. At the same time, Tianjing Hangzhou further seeks the introduction and layout of new varieties, and plans to cooperate with 1-2 new varieties every year. Tianjing Hangzhou will attract no less than 10 talents in the field of biological antibodies in five years, and cultivate more than 100 talents with advanced technology in the field of biological macromolecules. Commercial antibody production base will meet the GMP requirements of China, the United States and the European Union.